Can you believe it?
Despite all the gyrations, fear and euphoria in the past twelve months, the S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) has finished the financial year virtually where it started, gaining just 0.4% since June 30, 2014. Without today's gain of 0.7%, clearly we'd be in red.
However, if you'd invested in dividend-paying stocks and reinvested those dividends, you'd have gone close to matching the S&P/ASX 200 Net Total Rtn (INDEXASX: XNT) (ASX: XNT) return of 4.4% so far.
Here're another 10 stocks that more than doubled their share prices, which would have seen you beat the index handily:
| Company | Return since June 30, 2014 |
| Alexium International Group Limited (ASX: AJX) | 510% |
| Senetas Corporation Limited (ASX: SEN) | 383% |
| Impedimed Limited (ASX: IPD) | 368% |
| REVA Medical Inc (ASX: RVA) | 229% |
| Blackmores Limited (ASX: BKL) | 176% |
| Viralytics Ltd (ASX: VLA) | 174% |
| Australian Pharmaceutical Industries Limited (ASX: API) | 153% |
| Qantas Airways Limited (ASX: QAN) | 150% |
| Pro Medicus Limited (ASX: PME) | 143% |
| Site Group International Ltd (ASX: SIT) | 133% |
Source: CapitalIQ
One thing you might notice from the list above is the number of medical/health care stocks. Impedimed, Reva, Blackmores, Viralytics, API and Pro Medicus are the stocks I'm talking about. That's partly a result of their dominance of the top-performing stocks over the past year, but also the tailwinds the whole sector has behind it. It's one reason why my self-managed super fund (SMSF) is heavily weighted towards the healthcare sector. Another is the technology sector.
The problem with the above list is a simple one. We're looking in the rear view mirror when we should be looking where we are going. In a year's time, it's unlikely that any of these stocks will make the list again. The ability to double their share prices not once but twice will probably prove too much for most.
And that means identifying the factors that made the companies on this list successful and applying that knowledge to a list of companies we think can double over the next 12 months, starting here…
